Stock Watch

May 14th, 2013

Tesla Takes Off; Netflix Flies; Barnes & Noble Sputters IDSI Announces Ministry of Health Approval in Kuwait to Distribute CTLM(R), the innovative 3D Laser Breast Imaging System Press Release: Imaging Diagnostic Systems, Inc.

Symbol IMDS
Price     0.0002
Change 0.00

FORT LAUDERDALE, Fla., May 14, 2013 (GLOBE NEWSWIRE) Imaging Diagnostic Systems, Inc. (IMDS), a pioneer in laser breast imaging, announced today that it has received approval from the Ministry of Health in Kuwait to market and sell its innovative CTLM® in that country. Mareen Group Co., the exclusive distributor of CTLM® in Kuwait, has worked hard to achieve this significant accomplishment.

Ahmad Abdulrahman, General Manager of Mareen Group Co., comments: “We are honored and extremely pleased to achieve the approval of the Ministry of Health in Kuwait for the CTLM®. The CTLM®offers Kuwaiti women an imaging method without radiation, compression or contrast agents. In addition, the encouraging results of the published paper in the March 2013 edition of Clinical Imaging, a radiologist peer reviewed journal, shows the potential for this amazing modality. The results from that study, “CTLM®could distinguish benign lesions from malignant lesions and is not affected by breast density” are very important, especially regarding the dense breast population in Kuwait. Through upcoming installations, the women of Kuwait will hopefully benefit from this non-invasive and dignified option.

We are very excited and honored to announce the Kuwaiti Ministry of Health approval. This helps IDSI, through the efforts of Mareen Group Co., to expand the availability of CTLM® in the Middle East,” said Linda Grable, CEO of Imaging Diagnostic Systems, Inc. “Mareen Group Co. is an established and successful distributor who will assist our efforts to increase worldwide use and adoption of CTLM(R). Our success in receiving this approval in Kuwait should help us continue to drive the acceptance of the CTLM(R) worldwide; thereby assisting women’s imaging needs.”

Imaging Diagnostic Systems, Inc. is the developer of the CTLM® system; a revolutionary optical breast imaging device. Optical mammography is a diffuse optical tomography (DOT) technique that aims at detecting breast cancer. The CTLM® system utilizes patented continuous wave laser technology and computed algorithms to create 3D images of the breast. The procedure is non-invasive, painless, and does not expose the patient to ionizing radiation or painful breast compression. The CTLM® system has received certification and licenses to sell internationally through the following approvals; European CE marking, Health Canada, China SFDA, UL, ISO 13485:2003, FDA export certification. Marketing clearances pending are Mexico COFEPRIS and Russian GOST-R.

For more information, visit our website: www.imds.com As contemplated by the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future, anticipated, or projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates or predictions of future results or events and there can be no assurance that actual results or events will not materially differ from expectations. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc. is included in the Company’s filings with the Securities and Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.

Contact: Investor Relations, 954-581-9800

Imaging Diagnostic Signs Shimadzu Medical to Market Its CTLM® Laser Breast Imaging Device in Australia, New Zealand and the Pacific Islands

May 17th, 2012

FORT LAUDERDALE, FL–(Marketwire – May 14, 2012) - Imaging Diagnostic Systems, Inc. (OTCBB: IMDS), a pioneer in laser breast imaging, announced today that it has signed a distribution agreement with Shimadzu Medical to market and sell its Computed Tomography Laser Mammography (CTLM®) System in Australia, New Zealand and the Pacific Islands.

“This strategic move follows in line with our vision to be in the forefront of innovative technologies that will further enhance our business. The Directors of Shimadzu Corporation unanimously agreed that the CTLM® system could heighten our image in the breast imaging realm. IDSI has developed a high quality innovative breast imaging product that will expand our product range. Shimadzu is well positioned to provide ongoing sales, service and support for the CTLM given our history and expertise in the medical device arena. We are excited to make this innovative technology available to women in Australia, New Zealand and the Pacific Islands,” commented Nick Mascoulis, General Manager/Shimadzu Medical Systems (Oceania) P/L.

Shimadzu Medical Systems (Oceania) Pty Ltd is an Australasian subsidiary of Shimadzu Corporation, Kyoto, Japan. Shimadzu’s goal is to support a healthy, comfortable living for all people. They have strived to contribute to people’s health and well-being since their inception in 1875. Shimadzu focuses on the development of “molecular imaging technology” to enable detection of subtle symptoms before the onset of full-blown diseases.

Linda Grable, CEO of Imaging Diagnostic Systems, Inc., states, “IDSI is very excited to appoint Shimadzu Corporation, a leader of global technologies, as the distributor in Australia, New Zealand and the Pacific Islands. We are eager to work with Shimadzu to make CTLM® available to women in that part of the globe.”

About Imaging Diagnostic Systems, Inc.

Imaging Diagnostic Systems, Inc. is the developer of the CTLM system; a revolutionary optical breast imaging device. Optical mammography is a diffuse optical imaging technique (DOT) that aims at detecting breast cancer. The CTLM® system utilizes patented continuous wave laser technology and computed algorithms to create 3-D images of the breast. The procedure is non-invasive, painless, and does not expose the patient to ionizing radiation or painful breast compression. The CTLM® system has received certification and licenses to sell internationally through the following approvals; European CE marking, Health Canada, China SFDA, UL, ISO 13485:2003 and FDA export certification. Pending Mexico COFEPRIS and Russian GOST-R.

As contemplated by the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future, anticipated, or projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates or predictions of future results or events and there can be no assurance that actual results or events will not materially differ from expectations. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc. is included in the Company’s filings with the Securities and Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.